Author

Ke Xu

Institution: Bristol-Myers Squibb (United States)

Observed institution: Bristol-Myers Squibb (United States)

OpenAlex ID: A5123556868

Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer

2026 · Dung T Le, Gunnar Folprecht, et al. · Journal for ImmunoTherapy of Cancer · 12

Works count: 1

Citation count: 11

H-index: 1

I10-index: 1